Integra Therapeutics closes a new investment of €1.5M with the addition of Columbus Venture Partners to seed round

29/03/2022 Press release INTEGRA THERAPEUTICS CLOSES A NEW INVESTMENT OF €1,5 MILLION WITH THE ADDITION OF COLUMBUS VENTURE PARTNERS TO SEED ROUND. The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo Capital and Takeda Ventures. The Integra Therapeutics gene writing platform is one…

Integra Therapeutics cierra una ronda de €1,5M a la que acude Columbus Venture Partners

29/03/2022 Nota de prensa INTEGRA THERAPEUTICS CIERRA UNA NUEVA INVERSIÓN DE €1,5 MILLONES CON LA INCORPORACIÓN DE COLUMBUS VENTURE PARTNERS EN LA RONDA SEED. La biotecnológica completa así su ronda seed con un total de 6 millones de euros, liderada el pasado diciembre por AdBio Partners, Invivo Capital y Takeda Ventures. La plataforma de escritura…

Integra Tx secures €4.5M in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

02/12/2021 Press release INTEGRA TX SECURES €4.5 MILLION IN FUNDING FROM ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL AND TAKEDA VENTURES. The biotechnology company, which specialises in gene editing and was founded by researchers Marc Güell and Avencia Sánchez-Mejías of Pompeu Fabra University, got its start in Barcelona The investment will be used to develop an innovative…